Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more

Recent & Breaking News (NDAQ:MYGN)

Myriad Genetics Signs Definitive Agreement to Sell Myriad RBM to Q2 Solutions

GlobeNewswire May 24, 2021

Myriad Genetics Appoints Melissa Gonzales to Lead Women's Health Business

GlobeNewswire May 20, 2021

Myriad Genetics to Share New Data at 2021 ASCO Validating Personalized Breast Cancer Risk Assessments for Women of All Ancestries

GlobeNewswire May 19, 2021

Myriad Genetics CEO Paul J. Diaz to Present at Bank of America Securities 2021 Virtual Health Care Conference

GlobeNewswire May 5, 2021

Myriad Genetics Delivers 12% Sequential Revenue Growth in March 2021 Quarter, Company Executes on Strategic Transformation Initiatives

GlobeNewswire May 3, 2021

Myriad Genetics Signs Definitive Agreement to Sell Myriad Autoimmune's Vectra Testing Business to Labcorp

GlobeNewswire May 3, 2021

Myriad Genetics to Update Progress on Transformation Plan and Growth Initiatives, Share Long-Term Financial Outlook at 2021 Investor Day

GlobeNewswire May 3, 2021

Depression Disconnect: GeneSight® Mental Health Monitor Shows Misunderstanding of Depression and Treatment

GlobeNewswire April 28, 2021

Myriad Genetics to Release March 2021 Quarterly Financial Results on May 3, 2021, Host Investor Day on May 4, 2021

GlobeNewswire April 27, 2021

Myriad Genetics Signs Definitive Agreement to Sell Myriad myPath® Melanoma, LLC, Laboratory to Castle Biosciences

GlobeNewswire April 27, 2021

Sera Prognostics Appoints Robert G. Harrison as Chief Information Officer

GlobeNewswire March 31, 2021

Myriad Genetics Announces Eric Santa as Chief Growth Officer, Names New Diversity and Marketing Leaders

GlobeNewswire March 29, 2021

MYRIAD GENETICS ALERT: Bragar Eagel & Squire, P.C. Announces the Shareholder Class Action Against Myriad Genetics, Inc. Survives Motion to Dismiss and Encourages Long-term Investors to Contact the Firm

Business Wire March 23, 2021

Myriad Genetics Joins Forces with Intermountain Precision Genomics for a Comprehensive Offering of Germline and Somatic Tumor Testing Services

GlobeNewswire March 2, 2021

Myriad Genetics Delivers 6% Sequential Revenue Growth; Company Continues to Execute Strategic Transformation Plan

GlobeNewswire February 23, 2021

Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives

GlobeNewswire February 18, 2021

Myriad Genetics to Announce December 2020 Quarterly Financial Results on February 23, 2021

GlobeNewswire February 16, 2021

New Study from Leading University of Utah Radiation Oncologist Validates Ability of Myriad Genetics' Prolaris® test to Guide Treatment for Prostate Cancer

GlobeNewswire February 12, 2021

Myriad Genetics to Participate in Multiple Upcoming Health and Technology Conferences

GlobeNewswire February 11, 2021

GeneSight Psychotropic Test's Combinatorial Approach Proves Better than Single-Gene Testing at Predicting Patient Outcomes and Medication Blood Levels

GlobeNewswire February 8, 2021